23andMe Holding Co. Stock News

23andMe Holding Co. (ME) CEO Anne Wojcicki on Q2 2021 Results - Earnings Call Transcript

SUNNYVALE, Calif., Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be presenting at t

Nearly 500 companies are reporting quarterly earnings this week. The one in our watch list for Monday morning, Coty, beat estimates on both the top and bottom lines.

The genetics upstart is acquiring a telehealth platform.

Investors may see potential in the company's proposed acquisition of telehealth company Lemonaid.

By Day Hagan Asset Management SUMMARY With corporate earnings coming out in abundance, a plethora of domestic and international narratives, and now, from a price perspective, a short-term overbought c

Hims & Hers Health has had its biggest one-day loss in over two months, following its rival 23andMe's agreement to buy web-based healthcare platform Lemonaid Health. Hims & Hers is a telehealth platfo

23andme CEO Anne Wojcicki joins The Exchange to discuss her company's planned acquisition of Lemonaid, a telehealth company, and the future of genetic integration in health. For access to live and exc

Fresh off its SPAC IPO, 23andMe is buying another company.

Direct-to-consumer DNA testing firm 23andMe Holding Co said on Friday it would buy privately held company Lemonaid Health Inc for $400 million in a cash-and-stock deal, as it looks to expand into tele

23andMe Holding Co. ME, +1.27% said Friday it agreed to pay $400 million for Lemonaid Health Inc., the on-demand platform for accessing medical care and pharmacy services, in a bid to add telemedicine

A favorable mention on CNBC lit a fire underneath the biotech's stock this week.

SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial r

It needs to make money from something bigger than just its genetic test kits.

23andMe (ME) stock is running higher on Friday as investors pile on with heavy trading thanks to a recent interview on CNBC. The post ME Stock: 6 Things to Know About 23andMe as Shares Shoot Higher To